Eli Lilly and Co (LLY) : Sio Capital Management added new position in Eli Lilly and Co during the most recent quarter end. The investment management firm now holds 140,392 shares of Eli Lilly and Co which is valued at $11,262,246 , the company said in a statement filed on Aug 15, 2016 with the SEC.Eli Lilly and Co makes up approximately 5.05% of Sio Capital Management’s portfolio.
Other Hedge Funds, Including , Absolute Return Capital sold out all of its stake in LLY during the most recent quarter. The investment firm sold 256,256 shares of LLY which is valued $20,556,856.Advisors Asset Management boosted its stake in LLY in the latest quarter, The investment management firm added 27,776 additional shares and now holds a total of 192,219 shares of Eli Lilly and Co which is valued at $15,485,163. Eli Lilly and Co makes up approx 0.24% of Advisors Asset Management’s portfolio.Bb&t Securities boosted its stake in LLY in the latest quarter, The investment management firm added 3,305 additional shares and now holds a total of 54,090 shares of Eli Lilly and Co which is valued at $4,411,580. Eli Lilly and Co makes up approx 0.07% of Bb&t Securities’s portfolio.Mission Wealth Management reduced its stake in LLY by selling 65 shares or 1.8% in the most recent quarter. The Hedge Fund company now holds 3,544 shares of LLY which is valued at $293,160. Eli Lilly and Co makes up approx 0.07% of Mission Wealth Management’s portfolio.Gilman Hill Asset Management boosted its stake in LLY in the latest quarter, The investment management firm added 1,050 additional shares and now holds a total of 4,710 shares of Eli Lilly and Co which is valued at $384,289. Eli Lilly and Co makes up approx 0.15% of Gilman Hill Asset Management’s portfolio.
Eli Lilly and Co closed down -0.52 points or -0.67% at $77.23 with 35,44,701 shares getting traded on Thursday. Post opening the session at $77.75, the shares hit an intraday low of $76.8 and an intraday high of $78 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.